Compare Fidelity National Information Servcs Inc (FIS) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Mesoblast Limited — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Fidelity National Information Servcs Inc is far larger — about 10.1× Mesoblast Limited's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Mesoblast Limited for 15 Days on average.
| FIS | MESO | |
|---|---|---|
Market Cap | $17.71B | $1.75B |
Volume | 9,047,825 | 239,027 |
Sector | Technology | Health |
52-Week High | $67.94 | $20.96 |
52-Week Low | $32.44 | $13.19 |
Typical Hold Time | 88 Days | 15 Days |
Enterprise Value | $38.22B | $1.83B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
